DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
GlycoMimetics Announces Pricing of Public Offering of Common Stock
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $11.50 per share. The gross proceeds from the offering are expected to be $80.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by GlycoMimetics. The offering is expected to close on or about May 30, 2017, subject to customary closing conditions.
Jefferies LLC and Cowen are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. is acting as lead manager for the offering. GlycoMimetics has granted to the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less the underwriting discount.
+myBinderRelated Content
-
people & placesShengdar Q. Tsai, PhDDr. Shengdar Q. Tsai is an assistant mem...
-
people & placesJo Howard, MB BChir, MRCP, FRCPathJo Howard, MB BChir, MRCP, FRCPath, beca...
-
education & researchPediatric Residents’ Perceived Barriers to Opioid Use in Sickle Cell Disease Pain ManagementObjective: Current guidelines recommend...
-
education & researchEpisodic Patterns of High Emergency Department Utilization Among Sickle Cell Disease PatientsBackground: High utilization of emergenc...
-
news & eventsWebinar Series: Sickle Cell Science: Path to Progress – Sickle Cell Disease Care in the Emergency Department: ...To commemorate Sickle Cell Awareness Mon...
-
news & eventsA Health Note From Dr. Biree Andemariam, SCDAA Chief Medical OfficerWhat You Need to Know About the Coronavi...
-
videos & visualsRoald Dahl’s Marvellous Children’s Charity “Everyone’s Business” campaignhttps://www.youtube.com/watch?v=VqdP3Sxa...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.